Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The C-IT Neo Trial
NCT05289193Phase 2Active, not recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Mar 2022
- Primary completion
- Mar 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in melanoma, sponsored by Memorial Sloan Kettering Cancer Center. Started Mar 2022; status: active, not recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT05289193.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05289193.